Melvin LK CHUA | FRCR, PhD, FASCO

7y in the making!!!

As I always spoke about this, the field of #NasopharyngealCarcinoma leads the way in driving individualised treatment in #HeadNeckCancer

When we published our initial idea of stratifying patients by their early treatment response using #EBVDNA back then in 2018, we decided to test our idea formally with a trial, and kudos to a very talented #biostats and willing collaborators, we came up with EP-STAR

Very glad to see it finally published today in @Nature
🍸

nature.com/articles/s4158…

Not often do we publish 2 back to back guidelines on #NasopharyngealCarcinoma in @JCO_ASCO

Was a pleasure leading this monumental effort with @BrigetteMa2 @ASCO CSCO 💪🏻💪🏻💪🏻

Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

#ESMO2026

Is more always necessarily better?

GORTEC IDEAL randomised phase 2 trial presented by @YG_TAO

Doublet EGFR ADC and Anti-PD1 vs EGFR ADC alone before CRT

Safety analyses revealed higher G3 TRAEs but no influence on compliance to RT

@PBlanchardMD @PierluigiBonomo

#ESMO2026

Compelling data from investigators of KN412 on ctDNA to prognosticate

Baseline and rapid clearance of ctDNA were highly prognostic in HPV- HNSCC

More evidence supporting #PrecisionOncology in #HeadNeckCancer 💪🏻💪🏻💪🏻

#ESMO26

Packed room this morning at the #Multidisciplinary session on #NasopharyngealCarcinoma #NPC #HeadNeckCancer

3 perspectives on #MedicalOncology @AnnaSpreafico1
#RadiationOncology
#Surgery

Thanks to @myESMO for highlighting this rare but important condition!